Market Overview

XTL Biopharma Buys Stake in Proteologics from Teva

Share:
Related TEVA
Report Sees 'Cognitive Dissonance' In Mylan's Internal Price Target
Analyst: Mylan Shareholders Might Get Convinced By Vigodman Letter
Leading Stock Mallinckrodt Delivers Strong Results As Base Forms (Investor's Business Daily)

XTL Biopharmaceuticals Ltd. announced on November 21^st that it has acquired 4,620,356 shares, of Proteologics Ltd., from Teva Pharmaceutical Industries Ltd. (NYSE: TEVA) in consideration for an amount of approximately NIS 6.5 million, which represents an amount of NIS 1.405 per Share (approximately 22% premium). The Shares represent all of Teva's shares in Proteologics and represent approximately 31.35% of Proteologics issued and outstanding share capital.

Posted-In: News Asset Sales

 

Related Articles (TEVA)

Around the Web, We're Loving...

Get Benzinga's Newsletters